From Gilead Adds “Cornerstone” Cancer Drug in $21B Immunomedics Buyout:

Corner stone

Corner stone—

Image: iStock/Darrin Hughes
https://www.istockphoto.com/portfolio/darrinhughes?assettype=image&mediatype=photography&sort=best

Underwriters and Partners

Xconomy Insight

Sponsored · Webinar
Oct. 28 – Accelerating COVID-19 Drug Discovery: Qualified Assays for Proinflammatory Cytokines
How Functional Cell-based Assays Support Clinical Programs Managing Proinflammatory Cytokines Associated with High Mortality
Eurofins DiscoverX

Sponsored · Whitepaper
Decentralized Clinical Trials: The Call for a New Paradigm
Virtual/hybrid trials and decentralized research can better integrate healthcare into patients’ lives and accelerate approval of new medications
PRA Health Sciences

Sponsored · Whitepaper
The Importance of Early Key Opinion Leader Outreach in the Biologics & Biosimilars Marketplace
Acknowledging various stakeholder networks and regulatory environment variances is essential to uncover the right decision-makers in support of biologics or biosimilars
IBM Watson

Xconomy on Demand

We offer a number of ways to subscribe for free!